Mayo Foundation for Medical Education and Research

University of California

Euroimmun Medizinische Labordiagnostika Ag

Cz Biohub Sf, Llc.

Sean J Pittock

Vanda A Lennon

Andrew McKeon

Thomas J Kryzer

Josephe A Honorat

Lars Komorowski

Yvonne Denno

Ramona Miske

Madeleine Scharf

Christiane Radzimski

Joseph L DeRisi

Stefanie Hahn

Shannon Hinson

Mandy Unger

Caleigh Mandel-Brehm

Michael R Wilson

Brian O'Donovan

Divyanshu Dubey

Avi Gadoth

James P Fryer

This disclosure describes methods and compositions for detecting the presence of a Kelch-like protein 11 autoantibody in a biological sample. Also provided are methods of treating subjects with testicular cancer or a premalignant condition and paraneoplastic encephalomyelitis.

Autoantibodies as biomarker of paraneoplastic encephalitis associated with testicular cancer

A method for diagnosing a disease can include detecting, in a sample from a patient, an autoantibody binding to Septin-7. A polypeptide comprising Septin-7 or a variant thereof can be used for the diagnosis of a disease. Preferably, the polypeptide is used to detect an autoantibody binding to Septin-7 in a sample. A kit is useful for the diagnosis of a disease. The kit may include a polypeptide that includes Septin-7 or a variant thereof or a medical device that includes a polypeptide that includes Septin-7 or a variant thereof and an autoantibody to Septin-7.

Autoantibodies to Septin-7 and diagnosis of neurological disease

Methods and materials herein are useful for assessing and/or treating autoimmune ataxias associated with septin-specific autoantibodies (e.g., septin-5-specific autoantibodies). For example, septin-5 polypeptides are provided as well as methods for using septin-5 polypeptides to detect septin-5-specific autoantibodies and/or to treat a mammal having an autoimmune ataxia.

Assessing and treating autoimmune ataxia

This document provides methods and materials for detecting PCA-2-specific autoantibodies, which can be associated with paraneoplastic neurological disorders and cancers associated with PCA-2-specific autoantibodies.

Materials and methods for evaluating and treating cancer

The invention provides prognostic methods for evaluating the severity of NMO and NMO-associated diseases as well as methods of treating NMO and NMO-associated diseases.

Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive

The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).

Neuromyelitis optica autoantibodies as a marker for neoplasia

Growing community of inventors

Rochester, MN, United States of America

Sean J Pittock